Recurrent Focal Segmental Glomerulosclerosis in Renal Allograft Recipients: Role of Human Leukocyte Antigen Mismatching and Other Clinical Variables

Table 2

Demographics of recurrent Focal Segmental Glomerulosclerosis in renal allograft recipients from 1990 to 2007 at Montefiore Medical Center.

Data of all transplant recipients
	All transplants for primary FSGS (𝑛=131)	FSGS recurrence (𝑛=22)	No recurrence (𝑛=109)	𝑃 value
Age at transplantation (years)	29.28 ± 1.26	18.64 ± 2.86	31.43 ± 1.31	<.001
Male	71 (54%)	11 (50%)	60 (55%)	.82
Male^c	49 (37%)	7 (32%)	42 (39%)	.59
African American	52 (40%)	11 (50%)	41 (38%)	.32
White	66 (50%)	8 (37%)	58 (53%)
Other	13 (10%)	3 (14%)	10 (9%)
African American^c	31 (24%)	6 (27%)	25 (23%)	.65
White^c	51 (39%)	7 (32%)	44 (40%)
Other^c	10 (8%)	2 (9%)	8 (7%)
Live Donor	50 (38%)	10 (45%)	40 (27%)	.63
Cadaveric Donor	78 (60%)	12 (55%)	66 (61%)
Prednisone	117 (89%)	18 (82%)	99 (91%)	.75
Calcineurin Inhibitors	103 (79%)	16 (73%)	87 (80%)
Purine inhibitors	28 (21%)	6 (27%)	22 (20%)
Rapamycin	30 (23%)	4 (18%)	26 (24%)
Data for subgroup of pediatric patients
	All transplantsfor primary FSGS (𝑛=49)	FSGS recurrence (𝑛=19)	No recurrence (𝑛=30)	𝑃 value
Age at transplantation (years)	15.08 ± 0.62	13.79 ± 1.02	15.9 ± 0.76	.085
Male	27 (55%)	9 (47%)	18 (60%)	.56
Male^c	15 (31%)	6 (32%)	9 (30%)	.71
African American	23 (47%)	10 (53%)	13 (43%)	.80
White	17 (35%)	6 (32%)	11 (37%)
Other	9 (18%)	3 (16%)	6 (20%)
African American^c	11 (22%)	6 (32%)	5 (17%)	.63
White^c	10 (20%)	5 (26%)	5 (17%)
Other^c	7 (14%)	2 (11%)	5 (17%)
Live Donor	21 (43%)	8 (42%)	13 (43%)	.99
Cadaveric Donor	28 (57%)	11 (58%)	17 (57%)
Prednisone	38 (78%)	16 (84%)	22 (73%)	.061
Calcineurin Inhibitors	35 (71%)	13 (68%)	22 (73%)
Purine inhibitors	16 (33%)	6 (32%)	10 (33%)
Rapamycin	8 (16%)	3 (16%)	5 (17%)

^cnumber of subjects, corrected to exclude acute rejection.